US FDA approves Roxane's morphine sulfate solution
This article was originally published in Scrip
Executive Summary
The US FDA has approved Roxane Laboratories' (a US-based subsidiary of Boehringer Ingelheim) morphine sulfate oral solution in 100mg per 5ml and 20mg per 1ml presentations for the management of moderate to severe, acute and chronic pain in opioid-tolerant patients.